Anavex Life Sciences faces regulatory setbacks, pipeline doubts, and dilution risks. Click here to read my latest analysis of ...
NDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based on positive data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback